Scarica l'app Stockscreener
69.27
3.52%
-2.53
Dopo l'orario di chiusura:
69.30
0.03
+0.04%
Monopar Therapeutics Inc Borsa (MNPR) Ultime notizie
Form 4 Monopar Therapeutics Inc: Andrew Cittadine (COO) For: 30 September - Investing.com Nigeria
Form 4 Monopar Therapeutics Inc: Chandler Robinson (Director, CEO) For: 30 September - Investing.com India
Form 4 Monopar Therapeutics Inc: Quan Anh Vu (CFO) For: 30 September - Investing.com Canada
Monopar Therapeutics director Christopher Starr sells shares worth $659k By Investing.com - Investing.com Canada
Form 4 Monopar Therapeutics Inc For: 11 October By Investing.com - Investing.com Canada
Monopar Therapeutics stock faces insider selling after Q2 loss - AD HOC NEWS
Form 4 Monopar Therapeutics Inc For: 6 October By Investing.com - Investing.com Canada
After a $0.005-per-share option exercise, Monopar Therapeutics (MNPR) director sells 8,400 shares. - Stock Titan
180 shares cover CFO taxes as Monopar Therapeutics (MNPR) settles a 614-share stock grant. - Stock Titan
16,800 shares are proposed for sale by Monopar Therapeutics (MNPR) director Christopher Starr. - Stock Titan
Form 4 Monopar Therapeutics Inc For: 28 September By Investing.com - Investing.com Nigeria
Form 4 Monopar Therapeutics Inc For: 28 September By Investing.com - Investing.com South Africa
Form 4 Monopar Therapeutics Inc For: 28 September By Investing.com - Investing.com India
Form 4 Monopar Therapeutics Inc For: 28 September By Investing.com - Investing.com Canada
Form 4 Monopar Therapeutics Inc For: 28 September By Investing.com - Investing.com UK
Four share sales at $87.15 to $89.79: Monopar Therapeutics (MNPR) CEO also exercised options. - Stock Titan
Stock-option shares are proposed for sale by Chandler Robinson at Monopar Therapeutics (NASDAQ: MNPR). - Stock Titan
Monopar Therapeutics Is Maintained at Overweight by Barclays - Moomoo
MNPR Maintained by Barclays -- Price Target Raised to $145 - GuruFocus
Barclays Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Raises Target Price to $145 - Moomoo
Discipline and Rules-Based Execution in MNPR Response - Stock Traders Daily
Monopar Therapeutics shares technical analysis: $120.21 resistance in focus after rally - Traders Union
Monopar Therapeutics stock trades near record levels as investors react to insider selling and stron - ad-hoc-news.de
What's behind Monopar Therapeutics's latest 3.0% stock pullback? - Traders Union
Monopar Therapeutics director Kim Tsuchimoto sells $455,566 in shares By Investing.com - Investing.com Canada
Monopar Therapeutics (MNPR) director sells 4,090 shares after option exercises - Stock Titan
Monopar Therapeutics director Raymond Anderson sells $351,835 in stock By Investing.com - Investing.com Canada
Monopar (MNPR) insider sells at $110–113 after $30 option exercise - stocktitan.net
Will Monopar Therapeutics stock regain momentum as oversold conditions limit further selling? - Traders Union
Monopar Therapeutics director Raymond Anderson sells $351,835 in stock - Investing.com
Monopar director Kim Tsuchimoto sells $455k in common stock - Investing.com India
Monopar Therapeutics director Kim Tsuchimoto sells $455,566 in shares - Investing.com
Monopar director Kim Tsuchimoto sells $455k in common stock By Investing.com - Investing.com Nigeria
Monopar Therapeutics director Raymond Anderson sells $351k in stock By Investing.com - Investing.com Canada
Monopar Therapeutics Director Kim R. Tsuchimoto Executes Six-Tranche Stock Sale Under Rule 10b5-1 Plan - Kalkine Media
Monopar Therapeutics (MNPR) CMO uses plan to exercise options - stocktitan.net
Monopar Therapeutics director Raymond Anderson sells USD 349,125 of common shares - Bitget
Monopar Therapeutics (MNPR) director sells 3,142 shares in plan trade - stocktitan.net
Monopar Therapeutics acting CMO sells $111 of stock, exercises options - Investing.com
Monopar Therapeutics (MNPR) director sells 4,090 shares near $110 - Stock Titan
Monopar Therapeutics (MNPR) director plans $906K share sale - Stock Titan
Monopar Therapeutics stock resistance test: Key levels to watch - tradersunion.com
Monopar Therapeutics (MNPR) acting CMO plans 1-share sale - Stock Titan
Monopar (NASDAQ: MNPR) director to sell 6,284 shares - Stock Titan
Companies Like Monopar Therapeutics (NASDAQ:MNPR) Can Afford To Invest In Growth - webull.com
Monopar (MNPR) Quarter in Focus: EPS Clears the Reported Estimate in the Current Update; Trading Response: Shares Close 2.85% Lower in the Latest SessionForward EPS Estimate - vinanet.vn
Monopar (MNPR) Quarter in Focus: EPS Clears the Reported Estimate in the Current Update; Trading Response: Shares Close 2.85% Lower in the Latest SessionInvestor Earnings Call - vinanet.vn
Monopar (MNPR) Latest: Ends Lower by 2.85% at $107.72 in the Latest Reading; Technical Setup: Price Remains Between $102.33 Support and $113.11 Resistance at the CloseBreak of Structure - vinanet.vn
MNPR drops as short-term selling pressure persists - Traders Union
What's behind Monopar Therapeutics's latest stock pullback? - Traders Union
4.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):